Medical Journals

Regulation of Epstein-barr Virus Latency Type by the Chromatin Boundary Factor Ctcf.

Authors:
  • Chau Charles M
  • Zhang Xiao-Yong
  • McMahon Steven B
  • Lieberman Paul M

From: The Wistar Institute, Philadelphia, PA 19104, USA.

Journal of virology

  • Publish Date: Jun 2006
  • ISSN: 0022-538X
  • Volume: 80
  • Issue: 12
  • Pages: 5723-32
  • Medium: Print
  • Language: English
  • Citation (JAMA): Chau Charles M, Zhang Xiao-Yong, McMahon Steven B, et al. Regulation of Epstein-barr Virus Latency Type by the Chromatin Boundary Factor Ctcf.. J. Virol. Jun 2006;80:5723-32

Abstract

Epstein Barr virus (EBV) can establish distinct latency types with different growth-transforming properties. Type I latency and type III latency can be distinguished by the expression of EBNA2, which has been shown to be regulated, in part, by the EBNA1-dependent enhancer activity of the origin of replication (OriP). Here, we report that CTCF, a chromatin boundary factor with well-established enhancer-blocking activity, binds to EBV sequences between the OriP and the RBP-Jkappa response elements of the C promoter (Cp) and regulates transcription levels of EBNA2 mRNA. Using DNA affinity, electrophoretic mobility shift assay, DNase I footprinting, and chromatin immunoprecipitation (ChIP), we found that CTCF binds both in vitro and in vivo to the EBV genome between OriP and Cp, with an approximately 50-bp footprint at EBV coordinates 10515 to 10560. Deletion of this CTCF binding site in a recombinant EBV bacterial artificial chromosome (BAC) increased EBNA2 transcription by 3.5-fold compared to a wild-type EBV BAC. DNA affinity and ChIP showed more CTCF binding at this site in type I latency cell lines (MutuI and KemI) than in type III latency cell lines (LCL3456 and Raji). CTCF protein and mRNA expression levels were higher in type I than type III cell lines. Short interfering RNA depletion of CTCF in type I MutuI cells stimulated EBNA2 mRNA levels, while overexpression of CTCF in type III Raji cells inhibited EBNA2 mRNA levels. These results indicate that increased CTCF can repress EBNA2 transcription. We also show that c-MYC, as well as EBNA2, can stimulate CTCF mRNA levels, suggesting that CTCF levels may contribute to B-cell differentiation as well as EBV latency type determination.

Mesh Headings (Keywords): Binding Sites, Cell Line, DNA-Binding Proteins, Epstein-Barr Virus Nuclear Antigens, Gene Expression Regulation, Viral, Genome, Viral, Herpesvirus 4, Human, Humans, Proto-Oncogene Proteins c-myc, RNA, Viral, Repressor Proteins, Transcription, Genetic, Viral Proteins, Virus Latency


Check for Full Text / PubMed Unique Identifier (PMID): 16731911


This abstract is part of PubMed, a service of the U.S. National Library of Medicine. PubMed includes more than 17 million citations from MEDLINE and other life science journals for biomedical articles. See Copyright and Disclaimers.

Linked medical terms appearing on this page are added by Healia to help readers find more information and are not part of the original PubMed document.

The data herein was last updated on July 8th, 2008 and may not reflect the most current and accurate data available from NLM.


Advertisements

About | Privacy Policy | Business Solutions | Advertise | Contact | Add Healia to your site

©2012. Healia / Meredith Corporation  

Use of this site constitutes acceptance of our Terms of Service and Privacy Policy. All content on this Web site, including medical opinion and any other health-related information, is for informational purposes only and should not be used for a specific diagnosis or individual treatment plan for any situation. Use of this site and the information contained herein does not create a doctor-patient relationship. Always seek the direct advice of your doctor in connection with any questions or issues you may have regarding your own health or the health of others.